



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/</u> <u>Verified</u>
CASPR2 Ab IgG Screen by IFA, Serum	Detected		[<1:10]	19-259-900218	16-Sep-19 20:34:00	16-Sep-19 20:34:00	17-Sep-19 17:12:08
CASPR2 Ab IgG Titer by IFA, Serum	1:1280 *		[<1:10]	19-259-900218	16-Sep-19 20:34:00	16-Sep-19 20:34:00	17-Sep-19 17:12:13

16-Sep-19 20:34:00 CASPR2 Ab IgG Screen by IFA, Serum
 CASPR2 Antibody, IgG is detected. Titer results to follow.

16-Sep-19 20:34:00 CASPR2 Ab IgG Screen by IFA, Serum:
 INTERPRETIVE INFORMATION: CASPR2 Ab IgG w/Reflex to Titer,
 Serum
 Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy and Morvan syndrome. Tumors such as thymoma, small-cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

16-Sep-19 20:34:00 CASPR2 Ab IgG Titer by IFA, Serum:
 INTERPRETIVE INFORMATION: CASPR2 Ab Titer IgG by IFA,
 Serum

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab